A comparison of two DAAs used in a unique model of care to treat hepatitis C infections in New Jersey
Abstract
In this prospective observational study, we compare the efficacy of glecaprevir/pibrentasvir vs sofosbuvir/velpatasvir in treating hepatitis C within a unique model of care utilizing a combination of telehealth, an ambulatory van, case management, and a contracted pharmacy. Among 769 patients treated, 90.4% completed treatment, with 9.6% lost to follow-up. Both regimens demonstrated high completion rates and efficacy.
Full citation:
Slim J, Bellafiore P, Tempalski B, Rosmarin-DeStefano C, Leyden K, Torres J, Duprey S, Levaggi E (2024). A comparison of two DAAs used in a unique model of care to treat hepatitis C infections in New Jersey
Open Forum Infectious Diseases, 11 (12), ofae645. doi: 10.1093/ofid/ofae645. PMCID: PMC11600950.